Document is current
Any future updates will be listed below
-
Authors
Crook, Christiana http://orcid.org/0000-0003-2065-9817
Zhang, Ya-Han http://orcid.org/0000-0003-1684-2475
Li, Daneng http://orcid.org/0000-0001-5330-7522
- License Information
-
More Information
Article History
Accepted: 11 March 2022
First Online: 25 March 2022
Declarations
:
: No external funding was used in the preparation of this article.
: Daneng Li reports research funding to his institution from AstraZeneca and Brooklyn ImmunoTherapeutics. He serves as a consultant and has received honoraria from Adagene, Advanced Accelerator Applications, Bayer, Coherus, Eisai, Exelixis, Genentech, Ipsen Biopharmaceuticals, Lexicon, Merck, MiNA Therapeutics, QED, Servier, Sun Pharma, Taiho, and TerSera Therapeutics, all outside the submitted work. Christiana Crook and Ya-Han Zhang declare that they have no conflicts of interest that might be relevant to the contents of this article.
: Not applicable.
: Not applicable.
: Not applicable.
: Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.
: Not applicable.
: Christiana Crook and Daneng Li conceived the idea for this article. Christiana Crook performed the literature search and data analysis. All authors drafted and/or critically revised the work.
